NASDAQ:APVO - Aptevo Therapeutics Stock Price, Price Target & More

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Aptevo Therapeutics Inc (NASDAQ:APVO) announced its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.07. The biotechnology company had revenue of $4.07 million for the quarter, compared to analysts' expectations of $3.37 million. Aptevo Therapeutics had a net margin of 5.40% and a negative return on equity of 47.64%. View Aptevo Therapeutics' Earnings History.

Aptevo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Aptevo Therapeutics.

2 brokers have issued 1-year target prices for Aptevo Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they expect Aptevo Therapeutics' stock price to reach $10.50 in the next year. View Analyst Ratings for Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include Clementia Pharmaceuticals (CMTA), Synergy Pharmaceuticals (SGYP), GTX (GTXI), Syros Pharmaceuticals (SYRS), Bellicum Pharmaceuticals (BLCM), Dermira (DERM), Achillion Pharmaceuticals (ACHN), Axovant Sciences (AXON), American Brivision (Holding) (ABVC), Savara (SVRA), Albireo Pharma (ALBO), Tyme Technologies (TYME), Unum Therapeutics (UMRX), Corvus Pharmaceuticals (CRVS) and Verastem (VSTM).

Headlines about APVO stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aptevo Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 47.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Aptevo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (5.44%), JPMorgan Chase & Co. (1.13%), Victory Capital Management Inc. (0.96%), Alambic Investment Management L.P. (0.88%), Park West Asset Management LLC (0.82%) and Spark Investment Management LLC (0.58%). Company insiders that own Aptevo Therapeutics stock include Marvin L White and Randy Joe Maddux. View Institutional Ownership Trends for Aptevo Therapeutics.

APVO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Aptevo Therapeutics.

APVO stock was acquired by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., JPMorgan Chase & Co., Park West Asset Management LLC, Dimensional Fund Advisors LP, Spark Investment Management LLC, Citadel Advisors LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Aptevo Therapeutics.

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $4.98.

Aptevo Therapeutics has a market capitalization of $111.57 million and generates $14.66 million in revenue each year. The biotechnology company earns $6.97 million in net income (profit) each year or ($1.53) on an earnings per share basis. Aptevo Therapeutics employs 121 workers across the globe.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]